
Bristol-Myers (BMY) Stock Forecast & Price Target
Bristol-Myers (BMY) Analyst Ratings
Bulls say
Bristol-Myers Squibb is positioned for potential positive growth in the 2026 fiscal year, with a solid quarter expected for their Growth Products, a confident outlook for Eliquis sales, and promising upcoming clinical readouts. Their focus on developing drugs for key therapeutic areas and their ongoing efforts in mergers and acquisitions also bode well for their future success. These factors, combined with their projected financial data, make Bristol-Myers Squibb a favorable investment opportunity.
Bears say
Bristol-Myers Squibb is facing several downside risks, such as potential competition in the rare CV, I&I, and oncology space, clinical failure of their pipeline programs, regulatory delays, and macroeconomic or policy-related risks. While the company has made updates to their model, increasing their PoS for some of their drugs and updating revenue and EPS estimates, their dependence on the US market and potential competition may impact their future growth and profitability.
This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.
Bristol-Myers (BMY) Analyst Forecast & Price Prediction
Start investing in Bristol-Myers (BMY)
Order type
Buy in
Order amount
Est. shares
0 shares